FOXP3
Overview
FOXP3 is the master transcription factor of regulatory T cells (Tregs), and is used as a marker of immunoregulatory/counter-activation activity in tumor immune signatures.
Alterations observed in the corpus
- Component of the 20-gene Immunologic Constant of Rejection (ICR) signature as an immunoregulatory counter-activation marker in colon cancer PMID:37202560.
- FOXP3+ T regulatory cell surge in peripheral blood trended toward worse PFS (HR 1.42, P = .43) in the IMRT reirradiation + nivolumab trial for recurrent/second primary HNSCC (n=51) PMID:38780927.
- FOXP3 was used as a CD4+/CD8+/FOXP3+ immune-cell phenotype marker to define infiltrating populations in a 44-specimen CyCIF/GeoMx spatial atlas of HGSOC fallopian tube precursors; FOXP3+ regulatory T cells detected as part of the immune infiltrate across progressive precursor stages PMID:39386723.
- FOXP3 is a transcription factor stabilizing regulatory T cell (Treg) suppressive function in NPC; targeted indirectly by IKZF2 degraders (PLX-4545, DKY709) to reprogram Tregs and restore anti-tumor immunity. PMID:24952746
- Used as an IHC marker for Treg quantification (clone 236A/E7) in the nivolumab-treated melanoma cohort; contributed to immune-cell-population analyses of the tumor microenvironment PMID:29033130
Cancer types (linked)
- COAD — expression measured as part of the ICR signature in the AC-ICAM cohort, where ICR-high tumors carried better OS PMID:37202560.
- HNSC — FOXP3+ T-cell surge post nivolumab + IMRT reirradiation trended toward worse PFS; hypothesis-generating peripheral blood biomarker (HR 1.42, P = .43) PMID:38780927.
- HGSOC — FOXP3 used as a marker of infiltrating Treg populations in spatial immune profiling of fallopian tube precursor lesions PMID:39386723.
Co-occurrence and mutual exclusivity
- Co-expressed with CD274, CTLA4, IDO1, PDCD1 in the immunoregulatory arm of ICR PMID:37202560.
- FOXP3+ T-cell surge co-occurs with MKI67+PDCD1+CD4+ T-cell surge as peripheral immune pharmacodynamic markers in the HNSCC reirradiation + nivolumab trial PMID:38780927.
Therapeutic relevance
- Not reported as a direct target in the corpus; relevant as an ICR component for prognostic stratification PMID:37202560.
Open questions
- None flagged in the corpus.
Sources
This page was processed by entity-page-writer on 2026-05-11. - PMID:24952746
This page was processed by entity-page-writer on 2026-05-11. - PMID:29033130
This page was processed by wiki-cli on 2026-05-15.